Your browser doesn't support javascript.
loading
HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang, Douglas D; Zhang, Bin; Gu, Qingyang; Lira, Maruja; Xu, Qiang; Sun, Hongye; Qian, Maoxiang; Sheng, Weiqi; Ozeck, Mark; Wang, Zhenxiong; Zhang, Cathy; Chen, Xinsheng; Chen, Kevin X; Li, Jian; Chen, Shu-Hui; Christensen, James; Mao, Mao; Chan, Chi-Chung.
Affiliation
  • Fang DD; *Discovery Services, †Genomics Center, WuXi AppTec Co., Ltd., Shanghai, China;‡Pfizer Oncology Research Unit, San Diego, California; and §Department of Pathology, Shanghai Cancer Center, Fudan University, Shanghai, China.
J Thorac Oncol ; 9(3): 285-94, 2014 Mar.
Article in En | MEDLINE | ID: mdl-24496003
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyridines / Oncogene Proteins, Fusion / Receptor Protein-Tyrosine Kinases / Carcinoma, Non-Small-Cell Lung / Protein Kinase Inhibitors / DNA-Binding Proteins / Lung Neoplasms Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: J Thorac Oncol Year: 2014 Document type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyridines / Oncogene Proteins, Fusion / Receptor Protein-Tyrosine Kinases / Carcinoma, Non-Small-Cell Lung / Protein Kinase Inhibitors / DNA-Binding Proteins / Lung Neoplasms Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: J Thorac Oncol Year: 2014 Document type: Article Affiliation country: China